<DOC>
	<DOCNO>NCT00067639</DOCNO>
	<brief_summary>In recent year PBPC replace bone marrow source hematopoietic stem cell autologous transplantation . One cite advantage procedure avoidance bone marrow harvest , frequently require general anesthesia . Other advantage include fast neutrophil platelet engraftment time , fast immune recovery , decrease amount tumor contamination technical ability obtain stem cell patient previously consider unharvestable marrow fibrosis prior radiotherapy pelvis . Filgrastim emerge preferred cytokine stem cell mobilization base safety profile positive experience granulocyte donor however , number circulate CD34+ cell occur third day start filgrastim injection . Pegfilgrastim stimulate production maturation neutrophil precursor enhances function mature neutrophils manner filgrastim . Data form normal volunteer study patient cancer show prolonged serum level cytokine , `` self-regulation '' pegfilgrastim level function neutrophil count . This confer therapeutic advantage clinical setting allow less frequent dosing .</brief_summary>
	<brief_title>Pegfilgrastim ( Neulasta ) Stem Cell Mobilization Patients With Multiple Myeloma</brief_title>
	<detailed_description>Stem cell special type blood cell , able grow divide . Stem cell give patient high dose chemotherapy help restore blood production immunity . For autologous stem cell transplant , stem cell collect patient chemotherapy , `` transplant '' back patient treatment . Circulating blood contains small number stem cell . It often necessary use drug NeupogenTM , injection skin twice day three day , stem cell collect help move stem cell bone marrow circulate blood . When stem cell blood , collect easily . The study drug pegfilgrastim similar NeupogenTM , however , long last . Therefore , treatment give single injection rather several injection many day . For study , receive single injection pegfilgrastim skin . Starting 3 day injection , blood test ( 1-2 tablespoon ) day . These blood test use learn enough stem cell circulate blood start collection procedure test check side effect drug . These day blood test continue 10 day completion stem cell collection procedure . When stem cell count reach certain level ( usually 4 5 day injection ) , stem cell collection start do day enough cell collect transplantation . Before collection start , blood ( 1-2 tablespoon ) urine sample collect routine test . You also chest x-ray electrocardiogram ( ECG - test measure electrical activity heart ) . These test do make sure handle collection process . You central venous line ( CVL ) place . For procedure , catheter ( small flexible tube ) place large vein collar bone . The CVL use collect stem cell . You stem cell collect procedure call apheresis . This procedure similar donate platelet blood bank . In process blood collect CVL pass cell separator machine . White cell ( contain stem cell ) collect frozen remain blood give back . During apheresis procedure blood keep clot continuous injection ACD-A ( sodium citrate solution ) . This may cause loss calcium blood . To help side effect , calcium contain solution continuously injected process stem cell collection . The procedure take around 4-6 hour . If sufficient number stem cell collect single procedure , procedure repeat required number stem cell collect . The maximum number procedure 5 . If enough stem cell collect 5 procedure take study doctor discus treatment option . The stem cell collect `` transplant '' back high-dose chemotherapy part standard care . This investigational study . Pegfilgrastim FDA approve commercially available . It approve increase white blood cell count chemotherapy . However , use collection stem cell transplantation experimental . Up 48 participant take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . 1 . Age 18 year old 2 . Patients multiple myeloma undergo autologous peripheral blood stem cell transplantation PBPC cell collection without chemopriming . 3 . Zubrod performance status &lt; 3 ( Appendix E ) 4 . Serum bilirubin &lt; 1.5 time upper limit normal , serum SGOT SGPT &lt; 2 time upper limit normal , serum creatinine &lt; 2.0 mg/dl 5 . WBC &gt; 3,500/ul 6 . Platelet count &gt; 100,000/ul prior first apheresis procedure 7 . Patients receive prior chemotherapy . Only patient treat thalidomide , bortezomib , +/ dexamethasone eligible . 8 . Sufficient peripheral venous access central venous catheter 9 . Informed consent 1 . Serious intercurrent medical illness 2 . History bleed disorder ( except patient treat , myeloma related bleed disorder ) 3 . Untreated hypercoagulation abnormality 4 . Patients prior history pulmonary embolism , deep venous thrombosis require anticoagulant therapy , placement venous filter . 5 . Untreated symptomatic cardiac disease define leave ventricular EF &lt; 40 % NYHA functional class &gt; II ( Appendix F ) 6 . Uncontrolled infection define fever antibiotic within 72 hour registration . 7 . History allergy filgrastim , pegfilgrastim know hypersensitivity Ecoli derive protein . 8 . Palpable splenomegaly craniocaudal spleen length great 12 cm 9 . Pregnancy 10 . Use aspirin , ibuprofen contain product within 7 day enrollment 11 . History uncontrolled autoimmune disorder 12 . Sickle cell trait/sickle cell disease 13 . Women lactate breast feed 14 . 14 . Patients abnormal cytogenetics may secondary myelodysplasia ( 5 , 7 11q23 abnormality ) exclude 15 . Peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>PBSC mobilization</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
</DOC>